Literature DB >> 2357506

What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease?

T Pullar1, V Wright, M Feely.   

Abstract

A questionnaire designed to ascertain the risk of adverse effects which patients with rheumatic conditions would accept for a particular therapeutic outcome was administered to 50 patients. The same questionnaire together with 'potted' histories of five of the patients was sent to 10 consultant rheumatologists. The willingness of both patients and doctors to risk side-effects varied with both the severity of the side-effect and the potential therapeutic benefit. Doctors were more willing than patients to risk death or serious disability (Wilcoxon, P less than 0.01) for a particular expected benefit. Doctors were also more willing to risk side-effects in treating seropositive rheumatoid arthritis than in treating non-articular rheumatism. No correlation was seen for patients between acceptable risk and diagnosis, pain or smoking habits. The risks which both groups stated they were willing to accept were less than those apparently associated with antirheumatic therapy. The results disagreed markedly with those of a previous study, demonstrating the importance of the methods used in this type of work.

Entities:  

Mesh:

Year:  1990        PMID: 2357506     DOI: 10.1093/rheumatology/29.3.215

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  6 in total

Review 1.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  'Acceptable' risk of drug treatment.

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 3.  Postmarketing surveillance of quinolones, 1990 to 1992.

Authors:  P Davey; T McDonald
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Misoprostol/NSAID fixed combinations. Help or hindrance in clinical practice?

Authors:  A Isdale; V Wright
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

5.  Patient preferences for treatment of rheumatoid arthritis.

Authors:  L Fraenkel; S T Bogardus; J Concato; D T Felson; D R Wittink
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103

6.  Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis.

Authors:  Tuan Khai Huynh; Ann Ostergaard; Charlotte Egsmose; Ole Rintek Madsen
Journal:  Patient Prefer Adherence       Date:  2014-01-20       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.